



# Using Apple Watch to estimate Cardio Fitness with $VO_2$ max

May 2021

# Contents

<b>Overview .....</b>	<b>3</b>
Introduction.....	3
Definition .....	3
Measurement and Estimation .....	3
Utility.....	3
Genetics.....	4
Interventions.....	4
<b>Cardio Fitness on Apple Watch.....</b>	<b>4</b>
Metric Description.....	4
Development .....	7
Study Design.....	7
Statistical Methods .....	7
Results .....	8
Discussion .....	10
<b>Conclusions .....</b>	<b>12</b>
<b>References.....</b>	<b>12</b>

# Overview

With watchOS 7, Apple Watch Series 3 and later use an updated algorithm to estimate a user's cardio fitness level as measured by  $\text{VO}_2$  max – the maximum volume of oxygen an individual can extract from inhaled air. This update extends  $\text{VO}_2$  max estimates to lower ranges, while also expanding the availability of this metric. Additionally, with watchOS 7.2, users can view how their cardio fitness level is classified based on their age group and sex in the Health app on iPhone, and they can receive a notification if it falls within the low range. This paper provides a detailed understanding of the capabilities of these features, including testing and validation.

## Introduction

### Definition

$\text{VO}_2$  max is the maximum volume of oxygen an individual can extract from inhaled air and consume via cellular metabolism. As such,  $\text{VO}_2$  max is a good overall indicator of cardiorespiratory fitness (CRF), because it incorporates multiple organ systems and is influenced by a number of factors at various points along the pathway, from respiration to end-organ oxygen consumption.<sup>1</sup>  $\text{VO}_2$  max values are typically normalised for body mass and reported as millilitres of oxygen per kilogram of body mass in one minute (ml/kg/min). They normally decline with increasing age and, at a population level, differ across biological sexes.<sup>2</sup>

### Measurement and Estimation

$\text{VO}_2$  max is measured during cardiopulmonary exercise testing (CPET) – a procedure in which an individual is asked to ride a static bike or ambulate on a treadmill at increasing intensity levels while wearing a face mask, which enables the direct measurement of oxygen in inhaled and exhaled air.<sup>3</sup> In most cases, the volume of oxygen that individuals consume during testing plateaus even though their work increases. This plateau or  $\text{VO}_2$  peak is assumed to be, and is referred to as, the  $\text{VO}_2$  max, despite a lack of certainty that a true maximum has been achieved.<sup>4</sup>

In practice,  $\text{VO}_2$  max or CRF is more commonly estimated from measurements taken during submaximal exertion. This is typically because these tests are less expensive and less time intensive to complete than maximal CPET, they require less exertion from the participant and are more comfortable for them, and significant evidence exists to derive  $\text{VO}_2$  max from submaximal exertion.<sup>5</sup>

### Utility

CRF, as measured by  $\text{VO}_2$  max or the closely related metabolic equivalent (MET) – with 1 MET = ~3.5 ml/kg/min – has, over the last 30 years, been repeatedly shown to be a predictor of all-cause and cardiovascular mortality, as well as cardiovascular events for men and women.<sup>6,7,8</sup> In some studies, CRF was independent of, and more predictive than, well-known risk factors for cardiovascular and all-cause mortality, such as hypertension, obesity and hypercholesterolemia.<sup>9,10,11</sup>

Because of this prognostic utility, members of the medical and scientific community have advocated for the inclusion of measurements of CRF in routine medical practice as adjuncts<sup>12</sup> to, or even in place of, traditional risk models, such as Framingham.<sup>13</sup> This predictive utility also applies outside the general population to disease-specific cohorts, such as individuals with heart failure,<sup>14</sup> and in clinical decision-making related to specific events, such as perioperative management<sup>15,16</sup> and referral for cardiac rehabilitation.<sup>17</sup> In 2016, in response to these and other demonstrations of utility, the American Heart Association (AHA) advocated for the assessment of CRF on a more routine basis, making a case for fitness as a vital sign.<sup>5</sup>

## Genetics

Genetics are strongly correlated with an individual's VO<sub>2</sub> max and changes in VO<sub>2</sub> max in response to exercise. At baseline, genetic factors are believed to determine approximately 50 to 70 per cent of the VO<sub>2</sub> max differences observed between individuals<sup>18,19</sup> and approximately 20 to 60 per cent of the variation in VO<sub>2</sub> max improvements in response to exercise training.<sup>5,20</sup>

## Interventions


Improving or maintaining VO<sub>2</sub> max over time is strongly associated with decreased mortality. In a study of over 500 men followed for 11 years, Laukkanen et al. found that for every 1 ml/kg/min increase in VO<sub>2</sub> max, risk of death decreased by 9 per cent.<sup>21</sup> At a study level, high-intensity interval training yields the greatest improvements in VO<sub>2</sub> max.<sup>22,23,24</sup> Over the course of programmes that ranged from 6 to 12 weeks, improvements in VO<sub>2</sub> max were generally around 5 to 10 per cent (in ml/kg/min). It's important to note that decreases in VO<sub>2</sub> max with decreased activity or inactivity have been reported to be of a similar or greater magnitude (up to a 27 per cent decline) over far shorter time periods (2-3 weeks).<sup>25,26</sup> Increasing physical activity in the absence of improvements to VO<sub>2</sub> max doesn't appear to confer the same survival benefit in those whose VO<sub>2</sub> max increases compared with those whose VO<sub>2</sub> max doesn't.<sup>27</sup>

# Cardio Fitness on Apple Watch

This paper describes the development and validation of the Cardio Fitness metric – an estimate of VO<sub>2</sub> max using Apple Watch. The intended audience of this paper is researchers, healthcare providers and developers who may be interested in using this estimation in their work, as well as customers who would like to know more about VO<sub>2</sub> max and how it's measured and validated using Apple Watch. Additional information on how to set up and view VO<sub>2</sub> max estimates for Apple Watch can be found here: [support.apple.com/en-gb/HT211856](https://support.apple.com/en-gb/HT211856).

## Metric Description

Cardio fitness on Apple Watch is an estimation of a user's VO<sub>2</sub> max, in ml/kg/min, which is made by measuring a user's heart rate response to physical activity. Updates to the algorithm used to estimate VO<sub>2</sub> max in watchOS 7 extend estimates to lower ranges of cardio fitness (14 to 60 ml/kg/min) for users with Apple Watch Series 3 or later. A view of VO<sub>2</sub> max in the Health app in iOS 14 under Cardio Fitness is shown in Figure 1. A VO<sub>2</sub> max value may be generated after walking, running or hiking outdoors on relatively flat ground (i.e. graded less than a 5 per cent incline or decline) with adequate GPS, heart rate signal quality and exertion (approximate increase of 30 per cent of the range from resting heart rate to max). A user's first such workout won't generate an estimate, and a user needs to have worn Apple Watch for one day before a first estimate can be generated.



**Figure 1: Cardio Fitness in the Health app in iOS 14**

These estimates of  $VO_2$  max are based on submaximal predictions of  $VO_2$  max rather than peak  $VO_2$ . As such, users don't need to achieve peak heart rate to receive an estimate. However, a notion of peak heart rate is needed. Because of this, users who take medication that may reduce their peak heart rate can indicate that they're taking this medication in Health Details in the Health app to enable more accurate  $VO_2$  max estimates (see Figure 2).

With a feature introduced in iOS 14.3, users aged 20 and above have the option of being notified if their cardio fitness level, as measured by estimated  $VO_2$  max, is consistently and confidently low enough to suggest a risk of long-term health issues or current limitation in daily activities. For users aged 20-59, the threshold for notification is the lowest quintile for sex and age by decade, as determined by the Fitness Registry and Importance of Exercise National Database.<sup>2</sup> For users aged 60 and above, absolute  $VO_2$  max thresholds of 18 and 15 ml/kg/min are used for males and females, respectively, based on data that suggests these are the thresholds for independent living at the extremes of age in both sexes.<sup>28</sup> Users who want to receive Low Cardio Fitness notifications must opt in, which requires completing an onboarding experience in the Health app that describes the feature; collects information, such as age, sex and relevant medication, which is needed to provide an accurate alert; outlines factors that can lower your cardio fitness; and provides optional educational content describing the importance of  $VO_2$  max and potential causes of a notification (see Figure 3).




Figure 2: Medication that affects heart rate can be noted in Health Details in the Health app in iOS 14




Figure 3: Onboarding for Low Cardio Fitness notifications in the Health app in iOS 14

# Development

## Study Design

Apple collected data for the design and validation of the VO<sub>2</sub> max metric across multiple studies, approved by an institutional review board (IRB), involving participants who consented to the collection and use of their data for this purpose.

Study participants completed VO<sub>2</sub> max tests, VO<sub>2</sub> submaximal tests or both – referred to as cardiopulmonary exercise testing (CPET) – while wearing Apple Watch Series 4. A variety of CPET test protocols were used, including both treadmill and cycle ergometers. Each participant completed up to six CPETs over the course of the studies, with at least 10 days between consecutive tests to ensure participants had sufficient time to rest between tests and adequate periods for data collection before and after individual CPETs. CPET data was used to verify that the protocol was completed correctly and that participants reached at least 60 per cent of their predicted maximum heart rate. Tests for which there were a gas exchange abnormality, low-quality heart rate signal, detected arrhythmia, reported pain or biomechanical inefficiency were excluded from all further analyses. Tests that passed the verification steps were used in algorithm development. To obtain the reference VO<sub>2</sub> max of each participant, linear projections were made using heart rate and VO<sub>2</sub> in the submaximal range to determine VO<sub>2</sub> max based on age-predicted maximum heart rate. Predicted maximum heart rate was lowered for users on medication that limits heart rate, such as beta blockers, according to published predictions.<sup>29</sup>

In addition to wearing Apple Watch during invigilated CPETs, participants wore Apple Watch and carried iPhone during their day-to-day activities throughout the course of the studies. These activities included workouts logged by participants. Data from a variety of Apple Watch sensors (photoplethysmograph, accelerometer, gyroscope, barometer and GPS) was collected during this period and used in VO<sub>2</sub> max algorithm design.

A subset of study participants was withheld from all algorithm design data to verify algorithm accuracy and guard against overfitting. Algorithm performance was calculated by comparing the last valid VO<sub>2</sub> max estimate on Apple Watch with the average of submaximal projections from all curated CPETs for each participant unless otherwise specified.

## Statistical Methods

The validity of VO<sub>2</sub> max on Apple Watch was computed as the mean and standard deviation of errors between the last valid mean VO<sub>2</sub> max estimate on Apple Watch and the mean submaximal VO<sub>2</sub> max projection from all curated CPETs for each participant. Reliability, reported as intraclass correlation coefficient (ICC), was evaluated by calculating the absolute agreement per participant between the last valid VO<sub>2</sub> max estimate on Apple Watch and a previous VO<sub>2</sub> max on Apple Watch estimated at least 28 days prior. The consistency of VO<sub>2</sub> max on Apple Watch is expressed as the median and 90th percentile standard deviation per participant of all VO<sub>2</sub> max estimates on Apple Watch for participants who had at least five estimates. Finally, the availability of VO<sub>2</sub> max on Apple Watch is computed in two ways: as the percentage of all outdoor pedestrian workouts longer than 5.75 minutes from all participants yielding a VO<sub>2</sub> max estimate on Apple Watch, and as the percentage of participants who completed at least 10 outdoor pedestrian workouts longer than 5.75 minutes who received at least one VO<sub>2</sub> max estimate on Apple Watch after 10 workouts.


## Results

Baseline characteristics of the participants whose data was used for design and validation are summarised in Table 1.

**Table 1. Participant characteristics**

	Design (N = 534)	Validation (N = 221)
<b>Gender – number (%)</b>		
Female	191 (36)	94 (43)
Male	343 (64)	127 (57)
<b>Age – years* (mean ± SD)</b>	<b>53 ± 18</b>	<b>55 ± 17</b>
<b>Age distribution – number (%)</b>		
<45 years	207 (39)	74 (33)
45–54 years	67 (13)	26 (12)
55–65 years	57 (11)	36 (16)
>65 years	203 (38)	85 (38)
<b>Reference VO<sub>2</sub> max – ml/kg/min (mean ± SD)</b>	<b>31.7 ± 10.6</b>	<b>29.7 ± 10.5</b>
<b>Length of observation – days (mean ± SD)</b>	<b>441 ± 137</b>	<b>390 ± 138</b>
<b>Comorbidities – number (%)</b>		
Arthritis	51 (10)	17 (8)
Diabetes	38 (7)	23 (10)
History of stroke	9 (2)	5 (2)
Coronary artery disease	41 (8)	24 (11)
History of myocardial infarction	34 (6)	16 (7)
COPD	4 (1)	3 (1)
Heart failure	10 (2)	5 (2)
Hypertension	121 (22)	47 (21)
<b>Smoking status (cigarettes) – number (%)</b>		
Current smoker	5 (1)	1 (1)
Former smoker	63 (12)	37 (17)
Never smoked	300 (56)	129 (58)
Smoking status unknown	166 (31)	54 (24)
<b>BMI category – number (%)</b>		
Underweight (BMI < 18.5)	1 (<1)	2 (<1)
Normal weight (18.5 ≤ BMI < 25.0)	215 (40)	99 (45)
Overweight (25.0 ≤ BMI < 30.0)	220 (41)	77 (35)
Obese (BMI ≥ 30.0)	98 (18)	43 (19)
*Based on year of birth.		

Algorithm performance for the design and validation data sets is reported in Table 2. A plot of reference (average CPET-derived VO<sub>2</sub> max per user compared with final Apple Watch-estimated VO<sub>2</sub> max) for the design and validation participants is shown in Figure 4. Algorithm performance was assessed on data collected during workouts. For a subset of participants (132 design and 62 validation), VO<sub>2</sub> max was also estimated outside workouts during periods of outdoor walking to assess the ability to estimate VO<sub>2</sub> max when a workout hasn't been initiated on Apple Watch. In these users, non-workout estimates were an average of 0.32 ml/kg/min higher than workout estimates in the design group. No significant difference was detected between workout and non-workout estimates in the validation group.



**Figure 4: Reference compared with estimated VO<sub>2</sub> max (ml/kg/min) for participants in the design and validation sets**

**Table 2. VO<sub>2</sub> max performance**

Metric	Description	Design (N = 534)	Validation (N = 221)
<b>Validity</b>	Error (mean estimated VO <sub>2</sub> max – mean projected submaximal reference) – ml/kg/min (mean ± SD)	1.2 ± 4.4	1.4 ± 4.7
<b>Reliability</b>	ICC A-1 comparison of last VO <sub>2</sub> max estimate using data and metadata from only that session with a VO <sub>2</sub> max estimate more than 28 days previous using only data and metadata from that session – ICC [confidence interval]	0.89 [0.86, 0.91]	0.86 [0.80, 0.90]
<b>Consistency</b>	SD of pVO <sub>2</sub> max per user – ml/kg/min (% of pVO <sub>2</sub> max)		
	Median	1.2 (3.7%)	1.2 (3.4%)
	90th percentile	2.6 (7.6%)	2.6 (7.2%)
<b>Availability</b>	Percentage of outdoor pedestrian workouts longer than 5.75 minutes receiving an estimate	79%	78%
	Percentage of participants who completed at least 10 outdoor pedestrian workouts longer than 5.75 minutes and received at least one estimate in their first 10 workouts	93%	93%

## Discussion

Assessment of CRF using VO<sub>2</sub> max has received increasing attention as a means of risk stratification, with some advocating for its consideration as a vital sign.<sup>5</sup> In practice and despite demonstrated benefits in application, objective measurement of CRF using CPET remains infrequent in part due to expense, participant burden and limited acceptance as standard of care across multiple specialities.<sup>30</sup> Accurate estimation of a user's VO<sub>2</sub> max through wearable technology could expand CRF screening to a large segment of the population at lower cost, and it may enable remote monitoring of patients between clinical visits in some programmes, such as cardiac rehabilitation. Such accurate and available estimates of VO<sub>2</sub> max may also be used to guide risk stratification and response to programmes designed to reduce risk, such as preoperative assessment and rehabilitation.<sup>31</sup>

The improved algorithm for VO<sub>2</sub> max estimation on Apple Watch described here was designed for and validated in a population with reference VO<sub>2</sub> max covering a wide range of cardio fitness levels, as shown in Figure 4. Nearly half the study participants were over the age of 55, and approximately 10 per cent had known coronary artery disease. Racial and ethnic diversity in the study population didn't approximate the US population. However, heart rate – a key input to VO<sub>2</sub> max estimates on Apple Watch – has been shown to be consistently accurate across multiple skin tones in both internal and external studies.<sup>32</sup>

Extension of VO<sub>2</sub> max estimates to lower ranges in watchOS 7, combined with estimation outside workouts, increases the availability of this metric for individuals with low cardio fitness. Over 90 per cent of participants who completed at least one outdoor walk, outdoor run or hiking workout longer than three minutes, and tracked these using the Workout app, received at least one estimate of VO<sub>2</sub> max on Apple Watch. Increasing the number of outdoor pedestrian workouts will increase the likelihood and accuracy of a VO<sub>2</sub> max estimate on Apple Watch.

VO<sub>2</sub> max estimation by Apple Watch is accurate and reliable relative to commonly used methods of measuring VO<sub>2</sub> max, with an average error of less than 1 MET and an ICC more than 0.85. The accuracy of VO<sub>2</sub> max on Apple Watch approaches the accuracy of the reference; submaximal exercise testing protocols have previously been measured to have approximately zero mean error and a standard error of 1 MET.<sup>33</sup> In terms of test-retest reliability, VO<sub>2</sub> max on Apple Watch has an ICC of 0.87 in the validation data compared with 0.75 in submaximal treadmill testing.<sup>34</sup>

With the new algorithm, VO<sub>2</sub> max estimates for users who take medication that limits heart rate – such as beta blockers and calcium channel blockers – and report the medication in the Health app on iPhone paired to Apple Watch should be more accurate relative to estimates made in previous versions of iOS and watchOS. The handling of these medications doesn't differentiate dosage, cardioselectivity or intrinsic sympathomimetic activity of some beta blockers, all of which could be potentially meaningful inputs, but have been omitted in favour of usability. With this approach, the estimated error for users in the validation cohort who take beta blockers and calcium channel blockers decreased from 11.8 ± 4.0 ml/kg/min to 1.6 ± 3.1 ml/kg/min when the Health Details settings appropriately reflected their medication usage. Users who take medication that limits heart rate but don't enter this information in the Health app will receive higher-than-actual estimates; users who take low or as-needed doses of these medications that don't consistently reduce max heart rate (for example, propranolol for performance anxiety) are likely to receive more accurate estimates if they don't enter this information. Given the highly prevalent usage of these medications,<sup>35</sup> accounting for them appropriately is critical to estimating VO<sub>2</sub> max accurately, especially for older users.

In some conditions, a user's VO<sub>2</sub> max estimate may be inaccurate. Users with an incorrect age, sex or weight entered in the Health app may have consistently inaccurate VO<sub>2</sub> max estimates. Normal physiological changes associated with pregnancy may lead to inaccurate estimates. Individual estimates may be low if sensor data is recorded during behaviours that increase the user's work in ways that Apple Watch can't detect accurately. Common instances of such behaviours include carrying significant weight beyond body weight, such as a heavy rucksack or child, and walking or running on ground that increases the user's work, such as sand. Similarly, using an assistive device or pushing a pushchair may decrease availability or accuracy of VO<sub>2</sub> max estimates on Apple Watch. Factors that increase heart rate, such as dehydration, caffeine intake, extreme heat or recent transition to high altitudes, may also lead to underestimates. VO<sub>2</sub> max accuracy on Apple Watch can be increased by performing frequent outdoor pedestrian workouts, by achieving higher exertion during workouts and by wearing Apple Watch consistently throughout the day beyond typical workout sessions.

Users with chronotropic incompetence – a condition where heart rate doesn't increase appropriately to compensate for demand<sup>36</sup> – may receive overestimates of VO<sub>2</sub> max. Chronotropic incompetence is primarily associated with heart failure, which occurs in approximately 30 to 80 per cent (depending on diagnostic criteria) of patients with the condition.<sup>37</sup> It has also been linked to significant proportions of patients with chronic obstructive pulmonary disease (COPD),<sup>38</sup> lupus<sup>39</sup> and other autoimmune conditions.<sup>40</sup>

In addition to chronotropic incompetence, other medical conditions can also decrease the accuracy of VO<sub>2</sub> max estimates on Apple Watch. These include medical conditions or devices that decouple heart rate from movement or exercise (for example, pain, arrhythmias, pacemakers or cardiac-assist devices); medical conditions that severely limit exercise tolerance, preventing patients from reaching heart rates close to their predicted maximum heart rate (for example, peripheral arterial disease); and medical conditions that significantly increase the difficulty of ambulation, such as skeletal or neuromuscular conditions that cause gait inefficiency (for example, multiple sclerosis or cerebral palsy).

# Conclusions

With watchOS 7 on Apple Watch Series 3 and later, VO<sub>2</sub> max estimates have been expanded to lower ranges of cardio fitness, while providing users with the option to receive a notification if their cardio fitness level is low for their age and sex. This extended range, along with increased estimate availability and the option for users who are taking medication that limits their heart rate to receive more accurate estimates than were previously available, may increase researchers' and medical professionals' ability to use this metric for tracking fitness in older adults and in the presence of comorbid health conditions.

# References

- <sup>1</sup>Stringer WW. Cardiopulmonary exercise testing: current applications. *Expert Review of Respiratory Medicine*. 2010; 4(2): 179–188. doi: 10.1586/ers.10.8.
- <sup>2</sup>Kaminsky LA, Arena R, Myers J. Reference Standards for Cardiorespiratory Fitness Measured With Cardiopulmonary Exercise Testing: Data From the Fitness Registry and the Importance of Exercise National Database. *Mayo Clinic Proceedings*. 2015; 90(11): 1515–1523. doi: 10.1016/j.mayocp.2015.07.026.
- <sup>3</sup>American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. *American Journal of Respiratory and Critical Care Medicine*. 2003; 167(2): 211–277. doi: 10.1164/rccm.167.2.211.
- <sup>4</sup>Balady GJ, Arena R, Sietsema K, et al. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. *Circulation*. 2010; 122(2): 191–225. doi: 10.1161/CIR.0b013e3181e52e69.
- <sup>5</sup>Ross R, Blair SN, Arena R, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. *Circulation*. 2016; 134(24): e653–e699. doi: 10.1161/CIR.0000000000000461.
- <sup>6</sup>Blair SN, Kohl HW, Paffenbarger RS, et al. Physical Fitness and All-Cause Mortality: A Prospective Study of Healthy Men and Women. *JAMA*. 1989; 262(17): 2395–2401. doi: 10.1001/jama.1989.03430170057028.
- <sup>7</sup>Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. *JAMA Network Open*. 2018; 1(6): e183605. doi: 10.1001/jamanetworkopen.2018.3605.
- <sup>8</sup>Clausen JSR, Marott JL, Holtermann A, Gyntelberg F, Jensen MT. Midlife Cardiorespiratory Fitness and the Long-Term Risk of Mortality: 46 Years of Follow-Up. *Journal of the American College of Cardiology*. 2018; 72(9): 987–995. doi: 10.1016/j.jacc.2018.06.045.
- <sup>9</sup>Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. *JAMA*. 2003; 290(12): 1600–1607. doi: 10.1001/jama.290.12.1600.
- <sup>10</sup>Laukkanen JA, Kurl S, Salonen R, Rauramaa R, Salonen JT. The predictive value of cardiorespiratory fitness for cardiovascular events in men with various risk profiles: a prospective population-based cohort study. *European Heart Journal*. 2004; 25(16): 1428–1437. doi: 10.1016/j.ehj.2004.06.013.
- <sup>11</sup>Myers J, Nead KT, Chang P, Abella J, Kokkinos P, Leeper NJ. Improved reclassification of mortality risk by assessment of physical activity in patients referred for exercise testing. *The American Journal of Medicine*. 2015; 128(4): 396–402. doi: 10.1016/j.amjmed.2014.10.061.
- <sup>12</sup>Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA*. 2009; 301(19): 2024–2035. doi: 10.1001/jama.2009.681.
- <sup>13</sup>Nauman J, Nes BM, Lavie CJ, et al. Prediction of Cardiovascular Mortality by Estimated Cardiorespiratory Fitness Independent of Traditional Risk Factors: The HUNT Study. *Mayo Clinic Proceedings*. 2017; 92(2): 218–227. doi: 10.1016/j.mayocp.2016.10.007.
- <sup>14</sup>Orimoloye OA, Kambhampati S, Hicks AJ, et al. Higher cardiorespiratory fitness predicts long-term survival in patients with heart failure and preserved ejection fraction: the Henry Ford Exercise Testing (FIT) Project. *Archives of Medical Science*. 2019; 15(2): 350–358. doi: 10.5114/aoms.2019.83290.
- <sup>15</sup>Begum SSS, Papagiannopoulos K, Falcoz PE, Decaluwe H, Salati M, Brunelli A. Outcome after video-assisted thoracoscopic surgery and open pulmonary lobectomy in patients with low VO<sub>2</sub> max: a case-matched analysis from the ESTS database†. *European Journal of Cardio-Thoracic Surgery*. 2016; 49(4): 1054–1058. doi: 10.1093/ejcts/ezv378.
- <sup>16</sup>Bhagwat M, Paramesh K. Cardio-pulmonary exercise testing: An objective approach to pre-operative assessment to define level of perioperative care. *Indian Journal of Anaesthesia*. 2010; 54(4): 286–291. doi: 10.4103/0019-5049.68369.

- <sup>17</sup>Holmes AA, Phillips LM. Cardiopulmonary exercise testing and SPECT myocardial perfusion imaging: Pre-test probability is the key. *Journal of Nuclear Cardiology*. 2019; 26(1): 107–108. doi: 10.1007/s12350-017-0996-7.
- <sup>18</sup>Schutte NM, Nederend I, Hudziak JJ, Bartels M, de Geus EJC. Twin-sibling study and meta-analysis on the heritability of maximal oxygen consumption. *Physiological Genomics*. 2016; 48(3): 210–219. doi: 10.1152/physiolgenomics.00117.2015.
- <sup>19</sup>Bouchard C, An P, Rice T, et al. Familial aggregation of VO<sub>2</sub>(max) response to exercise training: results from the HERITAGE Family Study. *Journal of Applied Physiology*. 1999; 87(3): 1003–1008. doi: 10.1152/jappl.1999.87.3.1003.
- <sup>20</sup>Zadro JR, Shirley D, Andrade TB, Scurrah KJ, Bauman A, Ferreira PH. The Beneficial Effects of Physical Activity: Is It Down to Your Genes? A Systematic Review and Meta-Analysis of Twin and Family Studies. *Sports Medicine - Open*. 2017; 3(1): 4. doi: 10.1186/s40798-016-0073-9.
- <sup>21</sup>Laukkanen JA, Zaccardi F, Khan H, Kurl S, Jae SY, Rauramaa R. Long-term Change in Cardiorespiratory Fitness and All-Cause Mortality: A Population-Based Follow-up Study. *Mayo Clinic Proceedings*. 2016; 91(9): 1183–1188. doi: 10.1016/j.mayocp.2016.05.014.
- <sup>22</sup>Gist NH, Fedewa MV, Dishman RK, et al. Sprint Interval Training Effects on Aerobic Capacity: A Systematic Review and Meta-Analysis. *Sports Medicine*. 2014; 44: 269–279. doi: 10.1007/s40279-013-0115-0.
- <sup>23</sup>Sultana RN, Sabag A, Keating SE, et al. The Effect of Low-Volume High-Intensity Interval Training on Body Composition and Cardiorespiratory Fitness: A Systematic Review and Meta-Analysis. *Sports Medicine*. 2019; 49: 1687–1721. doi: 10.1007/s40279-019-01167-w.
- <sup>24</sup>Helgerud J, Høydal K, Wang E, et al. Aerobic high-intensity intervals improve VO<sub>2</sub>max more than moderate training. *Medicine & Science in Sports & Exercise*. 2007; 39(4): 665–671. doi: 10.1249/mss.0b013e3180304570.
- <sup>25</sup>Krogh-Madsen R, Thyfault JP, Broholm C, et al. A 2-wk reduction of ambulatory activity attenuates peripheral insulin sensitivity. *Journal of Applied Physiology*. 2010; 108(5): 1034–1040. doi: 10.1152/jappphysiol.00977.2009.
- <sup>26</sup>Taylor HL. The effects of rest in bed and of exercise on cardiovascular function. *Circulation*. 1968; 38(6): 1016–1017. doi: 10.1161/01.cir.38.6.1016.
- <sup>27</sup>Williams PT. Physical fitness and activity as separate heart disease risk factors: a meta-analysis. *Medicine & Science in Sports & Exercise*. 2001; 33(5): 754–761. doi: 10.1097/00005768-200105000-00012.
- <sup>28</sup>Paterson DH, Cunningham DA, Koval JJ, St Croix CM. Aerobic fitness in a population of independently living men and women aged 55–86 years. *Medicine & Science in Sports & Exercise*. 1999; 31(12): 1813–1820. doi: 10.1097/00005768-199912000-00018.
- <sup>29</sup>Brawner CA, Ehrman JK, Schairer JR, et al. Predicting maximum heart rate among patients with coronary heart disease receiving beta-adrenergic blockade therapy. *American Heart Journal*. 2004; 148(5): 910–914. doi: 10.1016/j.ahj.2004.04.035.
- <sup>30</sup>Forman DE, Myers J, Lavie CJ, et al. Cardiopulmonary Exercise Testing: Relevant but Underused. *Postgraduate Medicine*. 2010; 122(6): 68–86. doi: 10.3810/pgm.2010.11.2225.
- <sup>31</sup>Older PO, Levett DZH. Cardiopulmonary Exercise Testing and Surgery. *Annals of the American Thoracic Society*. 2017; 14(Supplement\_1): S74–S83. doi: 10.1513/AnnalsATS.201610-780FR.
- <sup>32</sup>Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in wearable optical heart rate sensors. *npj Digital Medicine*. 2020; 3(1): 18. doi: 10.1038/s41746-020-0226-6.
- <sup>33</sup>Foster C, Jackson AS, Pollock ML, et al. Generalized equations for predicting functional capacity from treadmill performance. *American Heart Journal*. 1984; 107(6): 1229–1234. doi: 10.1016/0002-8703(84)90282-5.
- <sup>34</sup>Eng JJ, Dawson AS, Chu KS. Submaximal exercise in persons with stroke: test-retest reliability and concurrent validity with maximal oxygen consumption. *Archives of Physical Medicine Rehabilitation*. 2004; 85(1): 113–118. doi: 10.1016/s0003-9993(03)00436-2.
- <sup>35</sup>Argulian E, Bangalore S, Messerli FH. Misconceptions and Facts About Beta-Blockers. *The American Journal of Medicine*. 2019; 132(7): 816–819. doi: 10.1016/j.amjmed.2019.01.039.
- <sup>36</sup>Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and management. *Circulation*. 2011; 123(9): 1010–1020. doi: 10.1161/CIRCULATIONAHA.110.940577.
- <sup>37</sup>Zweerink A, van der Lingen A-LCJ, Handoko ML, van Rossum AC, Allaart CP. Chronotropic Incompetence in Chronic Heart Failure. *Circulation: Heart Failure*. 2018; 11(8): e004969. doi: 10.1161/CIRCHEARTFAILURE.118.004969.
- <sup>38</sup>González-Costello J, Armstrong HF, Jorde UP, et al. Chronotropic incompetence predicts mortality in severe obstructive pulmonary disease. *Respiratory Physiology & Neurobiology*. 2013; 188(2): 113–118. doi: 10.1016/j.resp.2013.05.002.
- <sup>39</sup>Prado, DM Leite do, et al. Abnormal chronotropic reserve and heart rate recovery in patients with SLE: a case-control study. *Lupus*. 2011; 20(7): 717–720. doi: 10.1177/0961203310397081.
- <sup>40</sup>Pecanha T, Rodrigues R, Pinto AJ, et al. Chronotropic Incompetence and Reduced Heart Rate Recovery in Rheumatoid Arthritis. *Journal of Clinical Rheumatology*. 2018; 24(7): 375–380. doi: 10.1097/RHU.0000000000000745.